Clinical practice guidelines recommend behavioral change protocols for obesity treatment, such as the Diabetes Prevention Program, which involves a low-energy diet, physical activity recommendations, behavioral therapy, and frequent visits. Weight losses of 7-9% per year have achieve with this type of intervention. However, evidence suggests that a very low-energy diet may reach 10-15% weight loss and conduce superior clinical effects. Therefore, the objective will be to evaluate the efficacy of the Diabetes Prevention Program with a very-low energy diet and a low-energy diet on body weight change at four months in Mexican adults with obesity. The study will be a randomized controlled trial. Participants will be randomized to an intensive lifestyle change program with a very low-energy diet or an intensive lifestyle change program with a low-energy diet. The primary outcome will be a change in body weight. Secondary outcomes will be changes in waist circumference, body mass index, total body fat, fat-free mass, abdominal fat, blood pressure, and quality of life. Data will be analyzed on an intention-to-treat (ITT) using Student's t-tests or Mann-Whitney's U-test. The protocol was performed following the SPIRIT guidelines. Ethical approval was obtained from the Research Ethics Committee of the Department of Medicine of the University of Sonora.

Inclusion Criteria:

• Adults (≥18 and ≤55 years of age).
• Residents of the city of Hermosillo, Sonora.
• BMI ≥ 30 and ≤ 40.
• Availability of time to participate in the study, including initial and final measurements.
• Have a device with access to the internet
• Availability and possibility to acquire the indicated diet
• Send a report of food consumption for three days

Exclusion Criteria:

• Being a participant in a weight loss program.
• Weight loss major than 5% in the last six months.
• Have type 2 diabetes or hypertension (previous).
• Use of drugs with an effect on body weight ( steroids, injectable progestins, lithium, valproic acid, carbamazepine, antipsychotics, antidepressants, thiazolidinediones, levothyroxine, metformin, and anorexigenic drugs).
• Have a history of coronavirus disease with hospitalization or the presence of sequelae that prevent the intervention from being carried out.
• Have cancer, kidney disease, eating disorders, psychiatric disorder (depression) or other serious diseases, active biliary disease, or known asymptomatic gallstones.
• Pregnancy or breastfeeding.
• Use of medications for obesity.
• Use of illegal substances harmful to health (drugs).
• Illiteracy.

The data obtained will be available from the corresponding author on the research request.